Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer. (June 2021)

• Record Type: Journal Article
• Authors: Lapidari, Pietro; Gbenou, Arnauld; Havas, Julie; Martin, Elise; Pistilli, Barbara; Martin, Anne-Laure; Everhard, Sibille; Coutant, Charles; Cottu, Paul; Lesur, Anne; Lerebours, Florence; Tredan, Olivier; Vanlemmens, Laurence; Jouannaud, Christelle; Levy, Christelle; Rigal, Olivier; Fournier, Marion; Andre, Fabrice; Vaz-Luis, Ines; Di Meglio, Antonio
• Is Part Of: Breast. Volume 57(2021)
• Page Start: 43
• Page End: 48
• Publication Date: 2021-06
• Subjects: Breast cancer -- Survivorship -- Granulocyte-colony stimulating factors -- Health-related quality-of-life -- Patient-reported outcomes; Breast -- Diseases -- Periodicals; Breast -- Tumors -- Periodicals; Breast -- Periodicals; Electronic journals; Periodicals; 616
• DOI: 10.1016/j.breast.2021.02.014
• Languages: English
• ISSNs: 0960-9776

Abstract

Abstract: We assessed long-term associations of Granulocyte-Colony Stimulating Factors (G-CSF) use with patient-reported outcomes (PROs) and hematologic toxicity among chemotherapy-treated, early-stage breast cancer patients in CANTO (NCT01993498). Among 2920 patients longitudinally followed-up until year-4 after diagnosis, 49% used G-CSF. In multivariable-adjusted mixed-models, EORTC QLQ-C30 pain and summary score were not substantially different between groups (overall adjusted mean difference, use vs no-use [95%CI]: +1.27 [-0.33 to +2.87] and −1.01 [-1.98 to −0.04], respectively). PROs were slightly worse at year-4 among patients receiving G-CSF, although differences were of trivial clinical significance. No major differences were observed in leukocyte or platelet count over time. Highlights: Studies on long-term side effects of G-CSF, including on quality of life, are lacking. We evaluated PROs and hematological values until year-4 after diagnosis among women with early breast cancer receiving G-CSF. 49% women treated with adjuvant chemotherapy in CANTO (N = 2920) used G-CSF. Long-term PROs and hematological values were not substantially different in women using G-CSF or not. There were slightly worse outcomes at year-4 in patients using G-CSF, although of trivial clinical significance.